Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Intravenous Immunoglobulin Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The intravenous immunoglobulin market has experienced significant growth in recent years. This market is set to expand from $15.57 billion in 2025 to $16.86 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.3%. Historically, this growth can be attributed to several factors including an increasing prevalence of primary immunodeficiency diseases, innovations in immunoglobulin purification techniques, a rise in hospital-based IVIG administration, growing public awareness concerning autoimmune disorders, and the expansion of IVIG production capacities.
The intravenous immunoglobulin market is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of $23.44 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.6%. Factors contributing to this growth during the projection period include the rising need for home-based IVIG treatment, the creation of biosimilar IVIG products, the incorporation of automated infusion systems, a broadening range of applications in neurological conditions, and the expansion of immunoglobulin therapies in developing markets. Key trends identified for the forecast timeframe encompass personalized immunoglobulin treatment, IVIG administration at home, the evolution and uptake of biosimilars, improved purification and safety measures, and automated infusion systems.
Get A Free Sample Report With In-Depth Market Insights:
Intravenous Immunoglobulin Market Growth Backed By Core Demand Fundamentals
The expanding geriatric population is poised to advance the intravenous immunoglobulin market. This demographic, defined as individuals over 65 years old, often experiences compromised immune function and a scarcity of antibodies as they age, requiring immunoglobulins to supplement their antibody levels. This directly boosts the demand for intravenous immunoglobulins. For instance, in January 2024, the Population Reference Bureau, a Kenya-based Nonprofit organization, reported that the population of Americans aged 65 and older is projected to surge from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Furthermore, this age group’s proportion of the total population is expected to climb from 17% to 23% during the identical period. Hence, the increasing geriatric population will undoubtedly stimulate the growth of the intravenous immunoglobulin market.
Intravenous Immunoglobulin Market Segmentation: How Does The Market Break Down By Category?
The intravenous immunoglobulin market covered in this report is segmented –
1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications
4) By End-User: Hospitals, Clinics, Home Care
Intravenous Immunoglobulin Market Growth Trends Reshaping The Competitive Landscape
Key companies operating in the intravenous immunoglobin market are concentrating on bringing innovative products to market, such as plasma-derived medicines, and securing their endorsement from federal bodies, including the US FDA, to gain a competitive advantage. The release of an FDA-approved advanced IVIG solution represents the U.S. Food and Drug Administration’s endorsement of a new intravenous immunoglobulin (IVIG) therapy designed for treating specific medical ailments. For example, in June 2024, Biotest AG, a Germany-based supplier of plasma proteins and products, publicly announced its initial U.S. Food and Drug Administration (FDA) approval for Yimmugo, designated for addressing primary immunodeficiencies. Yimmugo, acting as an intravenous immunoglobulin, incorporates pooled human plasma-derived immunoglobulin G (IgG), which is essential for providing immune support to patients with PIDs. This approval emerges amidst a rising need for plasma-derived treatments, underscoring the requirement for effective therapeutic options for individuals with weakened immune systems. Yimmugo further enhances Grifols’ existing collection of intravenous and subcutaneous immunoglobulins, thereby offering more alternatives for patients who rely on these vital medications.
Intravenous Immunoglobulin Market Competitive Overview And Top Companies
Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.
View The Full Intravenous Immunoglobulin Market Report:
Intravenous Immunoglobulin Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the intravenous immunoglobulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
